Yangsoo Jang, M.D. Ph. D On behalf of CTO-IVUS investigator Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine,

Slides:

Advertisements

Similar presentations

Seoul National University Hospital CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation.

Advertisements

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

The Randomized Comparison of 6-month vs

Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With Coronary In-Stent Restenosis of Drug-

Final Three-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer The.

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.

Randomized Comparison of High-Dose Oral Vitamins versus Placebo in the Trial to Assess Chelation Therapy (TACT) Gervasio A. Lamas, MD, FACC Professor of.

Is Direct Stenting Superior to Stenting with Predilation in Patients Treated with Percutaneous Coronary Intervention? Results from a Meta-Analysis of 24.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Efficacy of high dose atorvaSTATIN loading before primary percutaneous coronary intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Jung-Sun.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting.

Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.

High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.

NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent Didier Carrié, MD,PhD On behalf.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

HOPE: Heart Outcomes Prevention Evaluation study

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

on behalf of the ABSORB II Investigators

EMPHASIS-HF Extended Follow-up

Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.

Achieving Long-Term Protection Post-MI

These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.

A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,

ENDEAVOR II Five-Year Clinical Follow-up

Ezetimibe/simvastatin

Svend A. Mortensen et al. JCHF 2014;2:

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Maintenance of Long-Term Clinical Benefit with

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Presentation transcript:

Yangsoo Jang, M.D. Ph. D On behalf of CTO-IVUS investigator Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea

1:1 randomization A total of 402 patients were finally enrolled after successful guidewire-crossing IVUS-guided group (n=201) (n=201) Angiography-guided group (n=201) (n=201) Total 467 patients with CTO were initially screened Exclusion Exclusion − Wiring failure ; 61 patients − Refusal of study enrollment ; 4 patients Clinical follow-up for 12 months # Primary endpoint; Composite of Cardiac death, MI, & TVR at 12 months 1:1 randomization R-ZES vs. N-BES

Follow-up duration (months) Number at risk Angiography-guided IVUS-guided HR=0.35, 95% CI = 0.13 – 0.97 p = month Cumulative incidence (%) 7.1% (14) 2.6% (5) Angiography-guided group IVUS-guided group (No. of events)

Follow-up duration (months) Number at risk Angiography-guided IVUS-guided * p = month Cumulative incidence (%) Angiography-guided group IVUS-guided group 2.0% (4) 0% (0) 5.2% (10) 2.6% (5) HR=0.48, 95% CI = 0.17–1.42 p = *Not calculable HR or CI because of no occurrence of the event

This CTO-IVUS study is the first randomized trial investigating the clinical benefits of IVUS guidance for CTO intervention after successful guidewire crossing in the era of new generation DES. This study demonstrated that … As compared to conventional angiography-guided CTO intervention, IVUS-guided CTO intervention As compared to conventional angiography-guided CTO intervention, IVUS-guided CTO intervention −caused a more frequent use of high-pressure post-dilation and a larger post-procedural MLD −finally, significantly improved clinical outcomes after DES implantation